Related Experiment Video
Updated: May 6, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men
Farrah J Mateen1, Wendy S Post, Ned Sacktor
1From the Department of Neurology (F.J.M.), Massachusetts General Hospital, Boston; Departments of International Health (F.J.M., N.S.), and Epidemiology (W.S.P., A.G.A.), Bloomberg School of Public Health, and Department of Medicine, Division of Cardiology (W.S.P.), the Johns Hopkins University, Baltimore; Department of Neurology (N.S., B.R.S.), the Johns Hopkins Hospital, Baltimore, MD; Departments of Neurology, Psychiatry, and Psychology (J.T.B.), University of Pittsburgh, PA; Department of Epidemiology, School of Public Health (R.D.), and Department of Medicine, School of Medicine (R.D.), University of California, Los Angeles; Department of Psychiatry (E.M.), Rush University Medical Center, Chicago; Feinberg School of Medicine (J.P.P.), Division of Infectious Diseases, Northwestern University, Chicago, IL; and Department of Biostatistics and Epidemiology (R.T.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Insights
The Framingham Risk Score for Stroke (FRS-S) underestimates stroke risk in HIV-infected men. This study highlights the need for improved stroke prediction models in this population.
Area of Science:
- Cardiology
- Infectious Diseases
- Epidemiology
Background:
- Cardiovascular disease is a leading cause of morbidity and mortality in people with HIV.
- Accurate stroke risk prediction is crucial for effective primary prevention strategies.
- The Framingham Risk Score for Stroke (FRS-S) is a widely used tool, but its performance in HIV-infected populations is not well-established.
Purpose of the Study:
- To evaluate the predictive accuracy of the Framingham Risk Score for Stroke (FRS-S) in HIV-infected versus HIV-uninfected men.
- To determine if FRS-S adequately captures stroke risk in the context of HIV infection.
Main Methods:
- Prospective cohort study (Multicenter AIDS Cohort Study - MACS) of HIV-infected (HIV+) and HIV-uninfected (HIV-) men who have sex with men (MSM).
- Ascertainment of stroke events over a 15-year period (1996-2011) among 3,945 participants.
- Calculation of FRS-S 10 years prior to stroke events and assessment by HIV status.
Main Results:
- Stroke incidence was higher in HIV+ participants (3.3/1,000 person-years) compared to HIV- participants (1.7/1,000 person-years).
- HIV+ men experiencing stroke were significantly younger than HIV- men (median age 51.3 vs 61.8 years).
- FRS-S indicated a higher average 10-year stroke risk in HIV- men (6.6%) than in HIV+ men (4.9%), despite higher incidence in the HIV+ group.
Conclusions:
- The Framingham Risk Score for Stroke (FRS-S) demonstrates systematically different predictions between HIV-infected and HIV-uninfected men.
- FRS-S underestimates the long-term risk of stroke in HIV-infected men.
- Current stroke risk assessment tools may require modification for HIV-infected individuals.
Objective:
To test the predictive accuracy of the Framingham Risk Score for Stroke (FRS-S) in HIV-infected (HIV+) vs HIV-uninfected (HIV-) men.
Methods:
The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of HIV+ and HIV- men who have sex with men (MSM) enrolled in 4 US cities. We ascertained all reported stroke events during a recent 15-year timeframe (July 1, 1996 to June 30, 2011) among 3,945 participants (1,776 HIV+ and 2,169 HIV-). For those with strokes, FRS-S were calculated 10 years before the stroke event and assessed according to HIV status.
Results:
A total of 114 stroke events occurred, including 57 HIV+ and 37 HIV- participants with first-ever strokes and 19 fatal strokes. The incidence of first-ever stroke was 1.7/1,000 person-years among HIV- and 3.3/1,000 person-years among HIV+ participants. Among those with strokes, HIV+ participants were younger than HIV- participants (median age 51.3 vs 61.8 years, p < 0.0001). For these men with stroke, the average 10-year risk of stroke was higher for HIV- MSM (6.6% [range 3%-26%] vs 4.9% for HIV+ MSM [range 0%-15%], p < 0.04). Traditional risk factors for stroke were similar among the Framingham cohort and the MACS HIV+ and HIV- participants.
Conclusions:
FRS-S prediction was systematically different in HIV+ vs HIV- men with stroke events. The FRS-S underestimates the long-term risk of stroke in HIV+ men.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
07:06Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
Published on: December 1, 2011
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Relative Risk
Acute Coronary Syndrome III: Diagnostic Studies